BONE-MARROW TRANSPLANTATION IN EUROPE - MAJOR GEOGRAPHICAL DIFFERENCES

被引:26
作者
GRATWOHL, A
HERMANS, J
GOLDMAN, JM
GAHRTON, G
机构
[1] KANTONSSPITAL,DEPT INTERNAL MED,DIV HAEMATOL,CH-4031 BASEL,SWITZERLAND
[2] LEIDEN UNIV,DEPT MED STAT,2300 RA LEIDEN,NETHERLANDS
[3] HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,LONDON W12 0HS,ENGLAND
[4] HUDDINGE UNIV HOSP,DEPT INTERNAL MED,S-14186 HUDDINGE,SWEDEN
[5] KAROLINSKA INST,HUDDINGE,SWEDEN
[6] KANTONSSPITAL,DEPT RES,CH-4031 BASEL,SWITZERLAND
关键词
D O I
10.1111/j.1365-2796.1993.tb00681.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In 1991 171 teams in 21 European countries performed 4976 bone marrow transplants. There were 1829 transplants from an HLA-identical sibling donor, 101 from a non-identical family member, 30 from a twin, 217 from an unrelated volunteer donor and 2799 autologous transplants. Indications for transplants were leukaemias in 2569 (52%), lymphoproliferative disorders in 1472 (30%), solid tumours in 549 (11%), aplastic anaemia and thalassaemia in 261 (5%), inborn errors in 97 and miscellaneous disorders in 28 patients. There are marked differences between the participating European countries. They relate to absolute numbers, indications and techniques. Less than 10 transplants per 10-million inhabitants are performed in Eastern European countries. Ten to fifty transplants per 10-million inhabitants are done in two, 50-100 transplants per 10-million inhabitants in five, 100-200 transplants per 10-million inhabitants in eight countries and more than 200 per 10-million inhabitants in one country (P < 0.01). The number of transplant teams ranges from less than one to twelve per 10-million inhabitants (P < 0.01). For the continent it becomes 3.3 per 10-million inhabitants. The reasons for these differences are not explained by this survey. The most likely explanation for the differences in transplant activity is availability of transplant beds, trained staff and resources. Bone marrow transplants are expensive. However, the demand is increasing and will increase further with the routine availability of unrelated volunteer donors. Clearly, criteria are required in Europe to define the indications and solutions to meet the legitimate requirements for transplantation in the various regions of Europe.
引用
收藏
页码:333 / 341
页数:9
相关论文
共 23 条
[1]   BONE-MARROW TRANSPLANTATION (BMT) VERSUS IMMUNOSUPPRESSION FOR THE TREATMENT OF SEVERE APLASTIC-ANEMIA (SAA) - A REPORT OF THE EBMT SAA WORKING PARTY [J].
BACIGALUPO, A ;
HOWS, J ;
GLUCKMAN, E ;
NISSEN, C ;
MARSH, J ;
VANLINT, MT ;
CONGIU, M ;
DEPLANQUE, MM ;
ERNST, P ;
MCCANN, S ;
RAGAVASHAR, A ;
FRICKHOFEN, N ;
WURSCH, A ;
MARMONT, AM ;
GORDONSMITH, EC .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 70 (02) :177-182
[2]   INCREASING UTILIZATION OF BONE-MARROW TRANSPLANTATION .2. RESULTS OF THE 1985-1987 SURVEY [J].
BORTIN, MM ;
RIMM, AA .
TRANSPLANTATION, 1989, 48 (03) :453-458
[3]  
DEWITTE T, 1990, BRIT J HAEMATOL, V74, P151
[4]  
FARROW DC, 1992, NEW ENGL J MED, V326, P1037
[5]   EUROPEAN EXPERIENCE OF BONE-MARROW TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY [J].
FISCHER, A ;
LANDAIS, P ;
FRIEDRICH, W ;
MORGAN, G ;
GERRITSEN, B ;
FASTH, A ;
PORTA, F ;
GRISCELLI, C ;
GOLDMAN, SF ;
LEVINSKY, R ;
VOSSEN, J .
LANCET, 1990, 336 (8719) :850-854
[6]   ALLOGENEIC BONE-MARROW TRANSPLANTATION IN MULTIPLE-MYELOMA [J].
GAHRTON, G ;
TURA, S ;
LJUNGMAN, P ;
BELANGER, C ;
BRANDT, L ;
CAVO, M ;
FACON, T ;
GRANENA, A ;
GORE, M ;
GRATWOHL, A ;
LOWENBERG, B ;
NIKOSKELAINEN, J ;
REIFFERS, JJ ;
SAMSON, D ;
VERDONCK, L ;
VOLIN, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (18) :1267-1273
[7]   BONE-MARROW TRANSPLANTATION WITH UNRELATED VOLUNTEER DONORS [J].
GAHRTON, G .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (12) :1537-1539
[8]   TREATMENT OPTIONS FOR BREAST-CANCER - BEYOND SURVIVAL [J].
GANZ, PA .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (17) :1147-1149
[9]  
GORIN NC, 1990, BLOOD, V75, P1606
[10]  
GRATWOHL A, 1990, BONE MARROW TRANSPL, V5, P159